Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation

Cancer Science

Volumn 100, Issue 4, 2009, Pages 730-736

  Hashimoto, Masayuki ^a,b   Ayada, Toranoshin ^a   Kinjyo, Ichiko ^b   Hiwatashi, Kiyokazu ^b   Yoshida, Hideyuki ^a,b   Okada, Yasunori ^b   Kobayashi, Takashi ^a,b   Yoshimura, Akihiko ^a,b,c  

^a KYUSHU UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; DEXTRAN SULFATE; GAMMA INTERFERON; I KAPPA B BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT1 PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; SYNAPTOTAGMIN I; SOCS1 PROTEIN, MOUSE; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; GENE DELETION; GENE SILENCING; KNOCKOUT MOUSE; MACROPHAGE; MELANOMA; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CROSS BREEDING; DISEASE MODEL; DNA METHYLATION; DRUG SCREENING; EXPERIMENTAL MELANOMA; GENETICS; IMMUNOLOGY; INFLAMMATION; KAPLAN MEIER METHOD; MOUSE MUTANT; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DNA METHYLATION; INFLAMMATION; KAPLAN-MEIERS ESTIMATE; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449083552     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01098.x     Document Type: Article

References (25)

1. Sakamoto H, Yasukawa H, Masuhara M et al. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 1998; 92: 1668-76.
2. Yasukawa H, Misawa H, Sakamoto H et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999; 18: 1309-20.
3. Marine JC, Topham DJ, McKay C et al. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 1999; 98: 609-16.
4. Alexander WS, Starr R, Fenner JE et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999; 98: 597-608.
5. Tanaka K, Ichiyama K, Hashimoto M et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 2008; 180: 3746-56.
6. Hanada T, Tanaka K, Matsumura Y et al. Induction of hyper Th1 cell-type immune responses by dendritic cells lacking the suppressor of cytokine signaling-1 gene. J Immunol 2005; 174: 4325-32.
7. Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol 2004; 22: 1546-53.
8. Hanada T, Kobayashi T, Chinen T et al. IFN gamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 2006; 203: 1391-7.
9. Yoshida T, Ogata H, Kamio M et al. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004; 199: 1701-7.
10. Yoshikawa H, Matsubara K, Qian GS et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
11. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999; 8: 265-77.
12. Lutz MB, Kukutsch N, Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
13. Fukao T, Frucht DM, Yap G, Gadina M, O'Shea JJ, Koyasu S. Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses. J Immunol 2001; 166: 4446-55.
14. Chinen T, Kobayashi T, Ogata H et al. Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFN gamma and IL-4 are involved. Gastroenterology 2006; 130: 373-88.
15. Naka T, Matsumoto T, Narazaki M et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci USA 1998; 95: 15577-82.
16. Starr R, Metcalf D, Elefanty AG et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci USA 1998; 95: 14395-9.
17. Metcalf D, Alexander WS, Elefanty AG et al. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 1999; 13: 926-34.
18. Wang JG, Wang DF, Lv BJ, Si JM. A novel mouse model for colitis-associated colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sulfate sodium. World J Gastroenterol 2004; 10: 2958-62.
19. Cui S, Reichner JS, Mateo RB, Albina JE. Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994; 54: 2462-7.
20. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994; 91: 9407-11.
21. Colombo MP, Mantovani A. Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 2005; 65: 9113-16.
22. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006; 97: 439-47.
23. Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature 2006; 442: 461-5.
24. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007; 178: 7571-80.
25. Muranski P, Boni A, Antony PA et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112: 362-73.